期刊文献+

他克莫司联合甲氨蝶呤治疗难治性类风湿关节炎临床分析 被引量:2

下载PDF
导出
摘要 目的探讨他克莫司联合甲氨蝶呤治疗难治性类风湿关节炎临床分析。方法选取该院2016年1—12月收治的难治性类风湿关节炎患者74例,按照病例编号分为观察组和对照组,对照组采用环磷酰胺和甲氨蝶呤联合治疗,观察组采用他克莫司和甲氨蝶呤联合治疗。两组患者的治疗前后进行血液检验、DAS28评分以及临床关节情况的对比。结果通过对比,观察组治疗后的血液检验、DAS28评分以及关节情况均优于对照组,差异有统计学意义(P<0.05)。结论对难治性类风湿关节炎患者采用他克莫司和甲氨蝶呤联合治疗,显著提高治疗效果。
作者 于树彬
出处 《双足与保健》 2017年第20期108-109,共2页 Biped and Health
  • 相关文献

参考文献3

二级参考文献47

  • 1Burkhard Kloesch,Tatjana Becker,Elisabeth Dietersdorfer,Hans Kiener,Guenter Steiner.Anti-inflammatory and apoptotic effects of the polyphenol curcumin on human fibroblast-like synoviocytes[J]. International Immunopharmacology . 2013 (2)
  • 2KLOESCH B, BECKER T, DIETERSDORFER E, et al. Anti-inflammatory and apoptotic effects of the polyphenol curcumin on human fibroblast-like synoviocytes[J]. Int Immunopharmacol, 2013, 15(2): 400-405.
  • 3AZIZI G, BOGHOZIAN R, MIRSHAFIEY A. The potential role of angiogenic factors in rheumatoid arthritis[J]. Int J Rheumat Dis, 2014, 17(4): 369-383.
  • 4ZHU Z, YIN Y, ZHENG K, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET/CT: a prospective proof of concept cohort study[J]. Ann Rheum Dis, 2014, 73(6): 1269-1272.
  • 5KIM S J, CHEN Z, CHAMBERLAIN N D, et al. Angiogen-esis in rheumatoid arthritis is fostered directly by toll-like receptor 5 ligation and indirectly through interleukin-17 induction[J]. Arthritis Rheum, 2013, 65(8): 2024-2036.
  • 6LUO Q, SUN Y, LIU W, et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide[J]. J Immunol, 2013, 191(10): 4969-4978.
  • 7HU W, XIA L J, CHEN F H, et al. Recombinant human endostatin inhibits adjuvant arthritis by down-regulating VEGF expression and suppression of TNF-α, IL-1β production[J]. Inflamm Res, 2012, 61(8): 827-835.
  • 8MARUOTTI N, CANTATORE F P, RIBATTI D. Putative effects of potentially anti-angiogenic drugs in rheumatic diseases[J]. Eur J Clin Pharmacol, 2014, 70(2): 135-140.
  • 9HARA M, ISHIGURO N, KATAYAMA K, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial[J]. Mod Rheumatol, 2014, 24(3): 410-418.
  • 10MUCKE H A. Iguratimod: a new disease-modifying antirheu-matic drug[J]. Drugs Today(Barc), 2012, 48(9): 577-586.

共引文献74

同被引文献7

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部